Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress In Oncology Programs And Expansion Into Autoimmune And Inflammatory Diseases December 12, 2024 At 8:30 Am EST
Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress In Oncology Programs And Expansion Into Autoimmune And Inflammatory Diseases December 12, 2024 At 8:30 Am EST
Zymeworks舉行研發日，強調在腫瘤項目中的持續臨床進展，以及在自免疫和炎症疾病領域的擴展，時間爲2024年12月12日東部標準時間上午8:30。
- Company on track to deliver five Investigational New Drug (IND) applications as part of '5 by 5' solid tumor strategy 18 months ahead of original target
- Nomination of ZW209, a novel trispecific T cell engager, as fifth development candidate in the Company's solid tumor portfolio
- Expansion into autoimmune and inflammatory diseases (AIID) and hematology oncology leverages the Company's clinically validated Azymetric technology platform and expertise in multispecific therapeutics
- ZW1528, the Company's first development candidate in AIID, demonstrates dual blockade of two complementary pathways of respiratory inflammation and offers potential benefit in mixed-type chronic obstructive pulmonary disease (COPD)
-
In-person and virtual R&D Day featuring Zymeworks research leadership and key opinion leaders to be held today at 8:30 am Eastern Standard Time (EST)
- 公司按計劃將在原定目標提前18個月交付五個新藥研究（IND）申請，作爲「5個5」實體腫瘤策略的一部分
- 提名ZW209，一種新型三特異性T細胞連接劑，作爲公司實體腫瘤產品組合中的第五個開發候選藥物
- 向自身免疫性和炎症疾病（AIID）及血液腫瘤的擴展利用了公司臨床驗證的Azymetric科技平台和多特異性治療的專業知識
- ZW1528，公司在AIID中的首個開發候選藥物，顯示出對呼吸道炎症兩條互補通路的雙重阻斷，並在混合型慢性阻塞性肺疾病（COPD）中提供潛在益處
- 今天東部標準時間（EST）上午8:30，將舉辦一場面對面和虛擬的研發日，屆時將有Zymeworks研究領導和關鍵意見領袖參與
VANCOUVER, British Columbia, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced highlights from its R&D Day reviewing the Company's development progress on its wholly-owned pipeline assets and expansion into new therapeutic areas in hematological cancers and autoimmune and inflammatory diseases (AIID).
溫哥華，英屬哥倫比亞，2024年12月12日（環球新聞稿）-- Zymeworks Inc.（納斯達克：ZYME）是一家臨床階段的生物技術公司，開發多種新型多功能生物治療藥物，以改善難治性疾病的標準治療，今天宣佈了其研發日的亮點，回顧了公司完全擁有的產品線資產的發展進展以及在血液腫瘤和自身免疫性與炎症疾病（AIID）新治療領域的擴展。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。